Trial Profile

Long-term Administration Study of MT-2412 in Patients With Type 2 Diabetes Mellitus

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Canagliflozin/teneligliptin (Primary)
Indications Type 2 diabetes mellitus
Focus Adverse reactions
Sponsors Mitsubishi Tanabe Pharma Corporation

Most Recent Events

13 Jun 2017 Results from phase 3 studies in Japanese patient with Type-2-diabetes-mellitus (MT-2412-J01, MT-2412-J02 and MT-2412-J03) presented at the 77th Annual Scientific Sessions of the American Diabetes Association
05 Aug 2016 Status changed from active, no longer recruiting to completed.
15 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com